FEATURED EDITORIAL
The FDA calls on your CDMO; inspectors are fortified by data in AI models, and appear practically clairvoyant. “It won’t be like the ‘old days,’” says David Grote of GrayMatters Partners, an organization that advises on quality systems and inspection readiness. The agency earlier rolled out Elsa, an AI-enable data architecture. Now its added an impressive HALO - Harmonized AI & Lifecycle Operations for Data.
- Five Raw Material Assumptions That Can Derail Your Outsourced Program
- Complete Response Letters For CGTs Share This Common Theme
- Your 7 Decisions To Make Before MES Configuration
- CDMOs Co-Author The RNA Ecosystem
- The Orange Book's Blind Spot: Process Stability And Capability
- Are You Falling Behind On Intelligent Pharmaceutical Manufacturing?
- DEA Reveals Hidden Costs Of Analytical Validation Guidelines
GUEST COLUMNISTS
-
The Orange Book's Blind Spot: Process Stability And Capability
The current system for assuring therapeutic equivalence contains structural blind spots. Companies must evolve rather than merely adding corrective actions.
-
Are You Falling Behind On Intelligent Pharmaceutical Manufacturing?
With a focus on small molecule drug product manufacture, let's take a closer look at the efficiencies gained through closed-loop control, PAT, digital twins, and more.
-
DEA Reveals Hidden Costs Of Analytical Validation Guidelines
By treating distinct validation guidelines as decision-making units, data envelopment analysis (DEA) allows for the mathematical evaluation of their resource efficiency.
-
Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
Systemic vulnerabilities exist in thermal uniformity assurance, steam penetration verification, regulatory fragmentation, and tech harmonization.
-
FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
The proposed revision reflects changes in packaging technology, drug delivery systems, quality risk management, and more that have occurred since 1999's guidance.
-
CDMO Selection Beyond Capabilities And Price
Some of the most useful information relevant to CDMO selection is also the hardest to obtain. Here are suggestions for uncovering data that tells the whole capability story.
-
August 2026 — CDMO Opportunities And Threats Report
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
-
Building Sustainable Biopharma Supply Chains Starts With Procurement
Nearly all the industry's emissions happen upstream from core manufacturing functions. This puts sustainability almost entirely on the shoulders of purchasing.
PHARMA OUTSOURCING WHITE PAPERS
-
Strategic Hiring For Scalable Success
Discover how a people-first talent strategy, purpose-driven culture, and cross-functional collaboration come together to support scalable growth and operational excellence in commercial manufacturing.
-
Spray Dried Biologics For Injectable Dosage Forms
Spray drying enables scalable production of stable, high‑concentration biologics as sterile powders, improving delivery, reducing costs, and overcoming limitations of traditional freeze‑drying methods.
-
A CFO's Guide To Driving Growth
Navigate the evolving biotech landscape and secure venture capital with insights on strategic partnerships and investor expectations.
-
Stabilizing Your Supply Chain In Times Of Global Volatility
Discover how a proactive, risk-based supply chain strategy can help strengthen resilience, mitigate disruption, and ensure continuity across your biotech and pharmaceutical operations.
-
A Comprehensive Solution For Adventitious Agent Testing
Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.
-
Aggregation In Antibody-Drug Conjugates: Causes And Mitigation
Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.
PHARMA OUTSOURCING APP NOTES & CASE STUDIES
- Prefiltration And Sterilizing Filtration Of Plasma Based Products
- Smart Scale-Up: Expanding Viral Vectors With Microcarrier Bead Technology
- Accelerating CAR T-Cell Therapy Manufacturing For Autoimmune Disease
- Leveraging Softgel To Extend Vinorelbine's Lifecycle, Improve Patient Convenience
- Developing A Project Management Office (PMO) At A Small Manufacturing Site
NEWSLETTER ARCHIVE
REPORTING
PRODUCTS & SERVICES
ON-DEMAND WEBINARS
- Synthetic DNA And The Future Of Genetic Medicine
- Solvent Recovery Systems For Sustainable Pharma Manufacturing
- Developing Custom GMP Lipids: A Patient-Driven Partnership
- Smarter Lead Selection And Faster Representative Material
- APAC Scaling AAV manufacturing to 1000 L: strategies for robust and reproducible production